Dexmedetomidine Inhibits Inflammation to Alleviate Early Neuronal Injury via TLR4/NF-κB Pathway in Rats with...

Area of Science:

• Neuroscience
• Pharmacology
• Immunology

Background:

• Traumatic brain injury (TBI) often leads to significant neuronal damage and inflammation.
• Understanding the molecular mechanisms underlying TBI is crucial for developing effective treatments.
• The Toll-like receptor 4 (TLR4)/nuclear factor-kappa B (NF-κB) pathway is implicated in neuroinflammation following TBI.

Purpose of the Study:

• To investigate the anti-inflammatory and neuroprotective effects of dexmedetomidine (DEX) in a rat model of TBI.
• To elucidate the potential mechanism of DEX action, specifically its role in the TLR4/NF-κB pathway.

Main Methods:

• A TBI model was established in rats, followed by random group allocation (Sham, Sham + DEX, TBI, TBI + vehicle, TBI + DEX).
• Brain water content, neuronal apoptosis (TUNEL assay), and inflammatory factors (TNF-α, IL-1β, IL-6, NF-κB) were assessed.
• Gene and protein expression levels of TLR4, HO-1, NQO-1, cleaved caspase-3, Bax, and Bcl-2 were analyzed using PCR, Western blot, and immunohistochemistry.

Main Results:

• TBI induced significant neuronal apoptosis and increased brain water content, which were attenuated by DEX.
• DEX treatment promoted TLR4 expression and its downstream factors HO-1 and NQO-1.
• DEX prevented the downregulation of inflammatory mediators including TNF-α, IL-1β, NF-κB, and IL-6.

Conclusions:

• Dexmedetomidine exhibits anti-inflammatory and neuroprotective properties in TBI rats.
• DEX alleviates neuronal injury by inhibiting inflammation, potentially through the TLR4/NF-κB signaling pathway.